Trial Profile
A Randomized, Multicenter, Double-Blind Phase 2 Study Of Palbociclib Plus Cetuximab Versus Cetuximab For The Treatment Of Human Papillomavirus-Negative, Cetuximab-Naïve Patients With Recurrent/Metastatic Squamous Cell Carcinoma Of The Head And Neck After Failure Of One Prior Platinum-Containing Chemotherapy Regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Cetuximab
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms PALATINUS
- Sponsors Pfizer
- 10 Oct 2022 Status changed from active, no longer recruiting to completed.
- 10 Oct 2022 Status changed from active, no longer recruiting to completed.
- 23 Jun 2022 Planned End Date changed from 30 Dec 2019 to 30 Sep 2022.